NASDAQ:SCYX SCYNEXIS (SCYX) Stock Price, News & Analysis $1.12 +0.01 (+0.90%) As of 10:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About SCYNEXIS Stock (NASDAQ:SCYX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SCYNEXIS alerts:Sign Up Key Stats Today's Range$1.11▼$1.1450-Day Range$0.99▼$1.4552-Week Range$0.90▼$3.07Volume18,143 shsAverage Volume218,074 shsMarket Capitalization$42.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company OverviewSCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Read More… SCYNEXIS Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreSCYX MarketRank™: SCYNEXIS scored higher than 14% of companies evaluated by MarketBeat, and ranked 902nd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for SCYNEXIS.Read more about SCYNEXIS's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of SCYNEXIS is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SCYNEXIS is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about SCYNEXIS's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.19% of the outstanding shares of SCYNEXIS have been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SCYNEXIS has recently decreased by 1.76%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.19% of the outstanding shares of SCYNEXIS have been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SCYNEXIS has recently decreased by 1.76%, indicating that investor sentiment is improving. News and Social Media1.1 / 5News SentimentN/A Search Interest4 people have searched for SCYX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows3 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.85% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about SCYNEXIS's insider trading history. Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Email Address SCYX Stock News HeadlinesSCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average - Time to Sell?February 14, 2025 | americanbankingnews.comSCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal InfectionsDecember 18, 2024 | markets.businessinsider.comHow You Could Invest in Elon’s ‘Final Move’What if I told you Elon Musk's next big venture could leave Tesla and SpaceX in the dust? It may sound unbelievable - but it's true. Elon's new AI startup could redefine the industry and create 10 TIMES more American millionaires than Tesla ever did. This isn't just another AI story. It's what I'm calling Elon's "Final Move."February 21, 2025 | Behind the Markets (Ad)Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)December 5, 2024 | markets.businessinsider.comSCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy RatingNovember 9, 2024 | markets.businessinsider.comSCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 6, 2024 | globenewswire.comInvestors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five yearsOctober 30, 2024 | finance.yahoo.comSCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 10, 2024 | globenewswire.comSee More Headlines SCYX Stock Analysis - Frequently Asked Questions How have SCYX shares performed this year? SCYNEXIS's stock was trading at $1.21 at the beginning of the year. Since then, SCYX stock has decreased by 7.9% and is now trading at $1.1150. View the best growth stocks for 2025 here. How were SCYNEXIS's earnings last quarter? SCYNEXIS, Inc. (NASDAQ:SCYX) issued its earnings results on Wednesday, November, 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.14. The company earned $0.66 million during the quarter. SCYNEXIS had a negative net margin of 425.41% and a negative trailing twelve-month return on equity of 66.21%. When did SCYNEXIS's stock split? SCYNEXIS's stock reverse split on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are SCYNEXIS's major shareholders? Top institutional investors of SCYNEXIS include Federated Hermes Inc. (7.63%), AMH Equity Ltd (1.65%), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.51%) and Northern Trust Corp (0.40%). Insiders that own company stock include Gonzalez David Angulo, Marco Taglietti and Scott Sukenick. View institutional ownership trends. How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SCYNEXIS investors own include Zomedica (ZOM), Jumia Technologies (JMIA), NIO (NIO), Nano Dimension (NNDM), Sorrento Therapeutics (SRNE), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings11/06/2024Today2/20/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCYX CUSIPN/A CIK1178253 Webwww.scynexis.com Phone(201) 884-5485Fax201-884-5490Employees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$67.04 million Net Margins-425.41% Pretax Margin-422.22% Return on Equity-66.21% Return on Assets-38.84% Debt Debt-to-Equity RatioN/A Current Ratio3.13 Quick Ratio3.13 Sales & Book Value Annual Sales$140.14 million Price / Sales0.30 Cash Flow$1.97 per share Price / Cash Flow0.56 Book Value$1.96 per share Price / Book0.56Miscellaneous Outstanding Shares37,950,000Free Float36,867,000Market Cap$41.93 million OptionableOptionable Beta1.52 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:SCYX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.